GSK plc GSK on Wednesday agreed to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa. Under the agreement, GSK will pay up to $2 billion in total cash consideration. This includes $1 ...

Those are just a few of the classic storylines Lifetime movie fans expect to see when they switch on the TV, and, this summer, GSK is adding another real-life danger to Lifetime's lineup ...

GSK plc GSK announced that it has signed an agreement with Massachusetts-based biopharmaceutical company Boston Pharmaceuticals to acquire the latter’s lead pipeline drug, efimosfermin alfa ...

GSK decided to abandon a TIGIT-targeted drug for cancer this week, then immediately hatched a plan to replace it with a late-stage candidate for metabolic dysfunction-associated steatohepatitis ...

GSK GSK1.80%increase; green up pointing triangle will acquire a liver-disease treatment from Boston Pharmaceuticals for up to $2 billion as it seeks to boost its pipeline of new drugs. The British ...

(RTTNews) - GSK plc (GSK, GSK.L) has entered into an agreement to acquire Boston Pharmaceuticals' BP Asset IX Inc. for $2 billion in total cash consideration, comprising a $1.2 billion upfront ...

The FDA has lifted its 19-month clinical hold on vaginal yeast infection drug Brexafemme (ibrexafungerp), according to the treatment's developer Scynexis. In its first-quarter report, the Jersey ...

GSK has announced that it will be acquiring Boston Pharmaceuticals’ phase 3-ready liver disease candidate in a deal worth up to $2bn. Efimosfermin alfa is an investigational drug in clinical ...

GSK has struck an agreement worth up to $2billion to buy a medicine that could treat fatty liver disease. The drugs giant plans to pay $1.2billion upfront to acquire Efirmosfermin from Boston ...

GSK will acquire a liver-disease treatment from Boston Pharmaceuticals for up to $2 billion as it seeks to boost its pipeline of new drugs. The British pharma giant said Wednesday that it will pay ...

Arab Finance: GlaxoSmithKline Egypt (GSK–Egypt) recorded EGP 59.123 million in consolidated net profits after tax and non-controlling interest in the first quarter (Q1) of 2025, against EGP 8.99 ...